GAO: FDA Must Boost Recruitment, Retention Of Clinical Trial Inspectors

FDA must take more steps to improve recruitment and retention of employees who conduct inspections at clinical research facilities, according to a new report from the Government Accountability Office (GAO), which notes the number of inspections conducted and enforcement actions taken have been decreasing for several years. FDA’s inspection responsibilities include overseeing clinical trials and other research involving human subjects, typically for brand-name or generic drugs seeking FDA approval. These inspections are conducted by the Bioresearch Monitoring (BIMO) program and...